For 21 years, the NYBA Annual Meeting has been the gathering place for the New York life science community. Bringing together hundreds of entrepreneurs, scientists, senior executives, financiers, and many others, the Annual Meeting is the largest bioscience meeting in the Northeast. With two days of high-impact information and insight from industry leaders, showcase presentations from emerging companies, and posters in Innovation Alley from the next generation of life scientists, you are sure to find a new partner, customer, technology, or contact. Early registration ends April 30, so register today and save up to $500: http://tinyurl.com/nyba2013

Drug development is becoming more complex and also more and more expensive. Those involved with the process of developing new therapeutics must understand the process and be able to navigate it with great skill. Failure is incredibly expensive.

The 2013 Drug Development Boot Camp will provide hands-on experience of the drug development process using a variety of methods. This will be an intensive but fun learning experience for all involved. You will learn in two days what it would take years to learn. A mixture of large/small pharma, and expert panel members will ensure panel discussions are relevant, responsive and applicable to situations that participants face. Participants must have 5-10 years of relevant experience and must be based in an appropriate company setting, or an academic or government setting involved with drug development. Scholarships may be available in a competitive process.

The 2012 Pharma Market Research Conference (Parsippany, New Jersey, February 7-8, 2012) is the premier gathering of senior level pharmaceutical, biotechnology, medical device, and diagnostics executives in market research. Nowhere else will you find the industry's best speakers and experts all under one roof: 60+ speakers in 2012!

More than 250 people came in 2011. They walked away with invaluable information, meaningful interaction with the industry's best speakers, as well as new business opportunities. This conference happens only once a year, so be sure to take advantage of this amazing opportunity! To register, to view last year's attendee list (250+ people!), or for more information, please visit http://pharmamarketresearchconference.com/, call +1-212-228-7974, or email info@pharmamarketresearchconference.com

The Life Sciences Internal Audit Forum will be a two-day, industry focused event, specific to those within Internal Audit, Corporate Audit and Audit Compliance.

Why Should You Attend?
This conference will bring together the leading senior executives from Pharmaceutical, Biotechnology and Medical Device Companies to discuss best practices on conducting internal audits including operations audits, clinical trial audits, third party audits and GRC audits for FCPA, Dodd-Frank and SOX.

Attendees will leave the conference with a much stronger understanding of how to approach internal auditing compliance to increase effectiveness while decreasing cost and time.

The Pharma CI Europe Conference & Exhibition (February 21-22, 2012, Zurich) is THE INDUSTRY'S GOLD STANDARD for senior level pharmaceutical, biotechnology, medical device, and diagnostics professionals seeking the latest news and the rare chance to network with all the industry's luminaries. More than 300 people came to the U.S. event in 2011! Now it's Europe's turn! This is the biggest and best gathering of pharmaceutical competitive intelligence thought leaders. 40+ speakers!

Join us at this premier gathering and network with other key decision makers as you learn about the most pressing and relevant issues facing the industry today. Enjoy the highest ratio of industry practitioners (pharma, biotech, medical device and diagnostics) of any pharma intelligence conference! For more information, please go to http://pharmaciconference.com/, call +1-212-228-7974, or email info@pharmaciconference.com

The 7th Drug and Medical Device Litigation Conferencec will be a two-day, industry focused event specific to those within Drug & Medical Device Litigation, Product Liability and Regulatory Affairs in the Medical Device, Biotech and Pharmaceutical industries.

Attending This Event Will Enable You to:

1. Review the current landscape of drug and medical device litigation
2. Learn strategies in settlements and mass tort issues
3. Manage litigation expenses in order to effectively manage costs
4. Review recent case rulings, including the Mensing and Levine cases
5. Take a view from the bench: explore drug and medical device litigation from a judicial point of view
6. Tackle product liability issues and challenges
7. Uncover the risks for drug and medical device companies when leveraging social media for marketing and advertising campaigns

CALBIO2012 is a statewide conference produced by BayBio and BIOCOM that brings together the life sciences sector in California and beyond: company executives and innovators, government, medical research and disease foundations, university transfer offices, philanthropists and investors. Built on the synergy between two leading life sciences clusters, CALBIO2012 identifies best practices and new models and fosters collaborations in research, development and product commercialization.

General contact info:
In Europe: Manuela Hildebrand EBD Group +49 89 2388 7560 mhildebrand@ebdgroup.com	In the USA: Christina Hundschell EBD Group +1 760 930 0500 chundschell@ebdgroup.com

BIO-Europe Spring® is the springtime counterpart to EBD Group's flagship conference, BIO-Europe®.

Featuring partneringONE®, EBD Group's sophisticated web-based partnering system, BIO-Europe Spring enables delegates to efficiently identify, meet and network with companies across the life science value chain.

BIO-Europe Spring also offers:

• a lively exhibition showcasing leading international life science organizations
• a program featuring senior executives and other thought leaders who openly share invaluable insights and opinions on many strategic industry issues
• company presentation tracks, which provide a unique opportunity for early stage projects, innovative start-ups, established biotechs and midsize pharma companies to get the attention of potential partners and investors.

Total value or cost competition: strategies to counter downward price pressure and drive product adoption

Join your industry colleagues at the largest meeting in Europe to find the solutions that will drive profits in this new world.

• Drive product adoption and counter downward price pressure: create the perfect health economic value for your products
• Engage all stakeholders through Digital: Use tablets and online platforms to enhance relationships with clinicians and payers
• Sell to the economic payer: Use persuasive health economic messages to sell the total value of your solutions
• Maximise your Key Accounts: Adapt your commercial model to meet the need of your customer and create one value based business case for your products and innovation
• Develop the perfect pricing structure: Increase profits through a pricing framework

Personalized medicine has moved from science fiction to clinical reality. Diseases are being diagnosed more quickly and accurately – or even prevented before they occur. Care is being tailored to the individual with drug treatments prioritized by how likely they are to work. Genetic sequencing is churning out data faster than ever before and at a price that is actually affordable. San Diego Venture Group's all-star panel will discuss today's obstacles and opportunities for personalized medicine and provide an outlook on how truly personal it will be in 10 to 15 years.

Moderated by BioWorld's own journalist Trista Morrison, she will guide the discussion amongst our panelists:

Joe Beery – SVP and CIO at Life Technologies
Alex de Winter – Partner with Mohr Davidow Ventures
Dave Anderson – CEO of Southern Ca at United Healthcare
Vance Vanier, M.D. – CEO and President of Navigenics

Visit www.sdvg.org/events/ to register or find out more.

This conference is a gathering place for the leaders of the orphan drug sector to unite with big pharma and the investment community to address strategies in developing/commercializing orphan products and capitalize on the multibillion dollar market to treat rare diseases.

Audience Profile:
Biotech CEOs, Big/Specialty Pharma Executives, Clinicians/Researchers, Patient Advocacy Groups, Regulatory Experts along with Private and Public Market Investors

Program Information:
Craig Simak
Chief Strategic Officer
IBF*International Business Forum
Direct Phone & Fax (516) 307-0743
Email: craig@ibfconferences.com

Throughout the medical device industry, manufacturers are struggling with the volume of requests from investigators who are interested in conducting research studies on new and existing products. While these studies were traditionally only led by a select number of key opinion leaders, many doctors and physicians in Europe are now considering these types of studies as a way to advance not only medical technology, but also their own profiles as industry experts. Executives in Medical and Clinical Affairs need to be prepared with strategies and policies which will govern how to best handle these types of research; especially given the rapidly evolving regulatory environment.

For pharmaceutical and medical device companies in Latin America, the sales training department is becoming increasingly more important to the overall business success. Due to the exponential rate of market growth in Latin America, a unique opportunity is presented for life science organizations to revitalize their sales training techniques. Establishing the importance of sales training to upper management during this stage of expansion in Latin American sales is extremely imperative and beneficial to training professionals. As such, Q1 Productions has worked closely with sales training and development leaders in building a two-day conference that will provide attendees with valuable tools and strategies to assist in further developing and strengthening sales training strategy specific to Latin America.

The MedTech Investing Conference has become the leading event for medical device investors, entrepreneurs and corporate business development executives. As in the past, this year's conference will feature industry leaders who will share their candid insights on the most critical issues in the sector today; while, at the same time, providing an intimate venue to network and to grow impactful relationships to help foster the development and financing of companies. This year, we will be joined by over 45 industry experts from around the nation, focusing on the broader theme of "THE NEW ERA OF INNOVATION".

Over the course of the past several years as the Medical Device Industry has continued to evolve, so has the role and importance of public relations and corporate communications. Various high-profile cases within the industry have required the skills of seasoned PR executives who understand how to best handle any situation and deliver important information without negatively impacting shareholder value for their company. From communicating during product crisis to furthering positive corporate reputation through initiatives aimed at higher levels of corporate social responsibility, the public relations and corporate communications executives have a wide range of ever increasing responsibilities.

Training and educating sales reps in the European medical device and diagnostic space posses a unique set of challenges and opportunities compared too many other world-wide industries. As the global economy and health policy evolves, so does the healthcare industry, sales reps and training methods. In order to accurately prepare sales reps to compete in today's marketplace, training and development professionals must be at the forefront of industry knowledge and technology advancement. This exciting, 3rd annual conference program will provide attendees with forward-thinking ideas from leading organizations and industry experts who will share and discuss the challenges that they have faced as well as key tools and solutions used when designing and executing cutting-edge sales training and education platforms.

The marcus evans 2nd Global Pharmacovigilance & Adverse Event Reporting Conference will host industry leaders from Pharmaceutical, Biotechnology and Medical Device Companies operating globally as they share best practices, strategies and tools on dissecting the impact of new global regulations, understanding adverse reporting requirements, strengthening data mining and REMS and deploying signal detection tactics.

Attendees will leave this conference with a better understanding of:

1. Current and pending global pharmacovigilance regulations to ensure compliance
2. Robust risk management plans and how to test their effectiveness
3. Data mining techniques to improve decision-making
4. Drug safety strategies from different global markets and industries
5. Internal measures to strengthen drug safety departments

For a $200 discount as a BioWorld subscriber, please contact Michele Westergaard at Michelew@marcusevansch.com

Hear from over 50 leading experts from BARDA, CDC, DOD, DTRA, FDA, MIDRP, NIAID, USAMRIID, WRAIR, and other key players in the CBRN community at the 10th Biodefense Vaccines & Therapeutics Conference, June 5-8, as they explore opportunities to speed development of needed MCMs against the public health threat of biodefense and emerging infectious diseases. Get progress-to-date of various MCM initiatives from the PHEMCE Review, how these initiatives are helping to incentivize private sector and academia participation, and what opportunities are being created to drive growth in MCM development for CBRN and emerging infectious disease threats.

Come to the BIO International Convention, June 18-21, 2012, in Boston, Mass., for the connections, partnerships and innovations to get business done. Join 15,000+ powerful biotech leaders from 65 countries and 4,000 companies for stellar networking events, a BIO Program offering important trends and perspectives on timely issues and a BIO Exhibition with 1,800+ companies showcasing the latest technologies, products and services. BIO One-on-One Partnering™ makes it easy to find potential partners and set up face-to-face meetings in the BIO Business Forum and the BIO Exhibition. Collaboration happens everywhere at BIO in Boston this June.

Please join us on Tuesday, August 21st for BIOCOM's Annual DeviceFest. This full day medical device and diagnostic conference will be at the Westin South Coast Plaza in Costa Mesa from 8:00 am to 5:30 pm. Attendees will hear from keynote speakers including Dr. StephenSpielberg, US Food and Drug Administration Deputy Commissioner, Office of Medical Products and Tobacco; David Sayen, Centers for Medicare and Medicaid Services Region IX Administrator; Dr. Joseph M. Smith, Chief Medical Officer and Chief Science Officer of the West Wireless Health Institute; and Josh Makower, Consulting Associate Professor of Medicine at Stanford University Medical School and Founder and CEO of ExploraMed. There will be presentations on topics including FDA compliance, finance, intellectual property, and commercial launch planning.

The Pharma CI Conference & Exhibition (September 11-12, 2012, Parsippany, NJ) is THE INDUSTRY'S GOLD STANDARD for senior level pharmaceutical, biotechnology, medical device, and diagnostics professionals seeking the latest news and the rare chance to network with all the industry's luminaries. More than 300 people came in 2011! This is the biggest and best gathering of pharmaceutical competitive intelligence thought leaders (75+ speakers)!

Join us at this premier gathering and network with other key decision makers as you learn about the most pressing and relevant issues facing the industry today. Enjoy the highest ratio of industry practitioners (pharma, biotech, medical device and diagnostics) of any pharma intelligence conference!

This is the only event featuring a world-class line up of speakers and panelists offering their unique insights and expertise on the topics you care about most! For more information, please go to http://pharmaciconference.com/, call +1-212-228-7974, or email info@pharmaciconference.com

BIOSPAIN 2012 will be held in its 6th edition in Bilbao (19th-21st September 2012) featuring a trade exhibition, a partnering event, an investment forum, the BIOTEC 2012 scientific congress, top level seminars & conferences and a career fair with a well balanced mixture of local and international private companies, universities, overseas clusters, research institutes and governmental bodies.

Since its first edition, launched back in the year 2003, it has become one of the leading biotechnology events in Europe. In its 5th edition (2010), held in Pamplona (Navarre, Spain), Biospain attracted over 1.300 delegates, 650 companies from 25 countries, featured 168 exhibitors and over 2.100 one-to-one partnering meetings were held, becoming the 7th largest biotech partnering event organized in 2010.

AdvaMed 2012 is the premier MedTech Conference, bringing over 800 companies together in a uniquely multifaceted environment for business development, capital formation, regulatory education, and networking. An event rich in international flavor and featuring a deep, diverse attendee list that includes influential policy makers, business executives, and media, AdvaMed 2012 seeks to advance industry discussion from key perspectives through detailed panel sessions, executive forums, and more. It is the most efficient, cost-effective, eye-opening, and exciting event out there, a "must-attend" for any MedTech company. Whatever your goals may be, you are sure to accomplish, and even surpass them, at AdvaMed 2012.

Life Science Professionals — Network with 500+ Bio, Pharma & Medical Device Professionals. The Conference connects professionals from across the nation to discuss trends & issues, including product development, scientific research, business development, financing & public policy.

Register now! http://www.bioflorida.com/conference.

Join over 1,100 Top Healthcare Executives, Investors, Entrepreneurs, VCs and Clinicians at Cleveland Clinic's 10th Annual Medical Innovation Summit: Innovative to the Bone. October 29-31, 2012, Cleveland OH. Registration, Agenda, Speakers and Details: www.ClevelandClinic.org/Summit

Global biopharma industry sees opportunity in Russia

Top executives from companies as diverse at Medtronic, Pfizer, EADS, Google, Sanofi Pasteur and Greylock Partners descended on Moscow for the inaugural Open Innovations Forum in Moscow last November. The event that brought them together – along with the likes of Russian Prime Minister Dmitry Medvedev, Richard Branson, celebrity journalists as well as MIT and Harvard professors– was a conference dedicated to a range of high-tech sectors, with a particular focus on biopharmaceuticals. G. Steven Burrill, whose firm established a Moscow office the same month, gave a keynote speech at an Open Innovations Forum panel discussions dedicated to venture investments in the pharmaceutical sector. The panelists discussed a number of new opportunities in Russia for both R&D and the production and commercialization of advanced biopharmaceuticals. The Russian government is offering lucrative tax privileges and access to superior research facilities to foreign companies ready to locate technology and expertise in Russia. It has also taken a series of measures to stimulate private investment in healthcare, in particular by eliminating the tax on profit for private clinics. The American drug developer Selecta Biosciences established a Russian subsidiary and research center in Russia last fall. Major life sciences investors such as Domain Associates have also taken notice; Domain invested millions of dollars in its Russia-focused venture in 2012.

There is substantial unmet demand for modern life sciences products in Russia. The government is modernizing a decaying healthcare system by building new hospitals and introducing innovative technologies. Russia's sovereign investment funds are backing innovative industries and supporting international co-investment. The government is working directly with business leaders to improve the country's attractiveness as an investment destination. According to its Chairman, Vladislav Surkov, the Open Innovations Forum was established to be, "a venue for discussions with our foreign partners…to achieve practical goals in the form of research and development projects". In fact, considerable progress has already been made toward these goals, as a biotechnology revolution gathers steam in Russia.

Russia committed to building a global biotech hub in Moscow

Perceptive international investors have sensed the change in the landscape of healthcare and medicine in Russia. What has changed? The government is backing its optimistic words about fostering technological innovation with billions of dollars in investment. Life sciences and biopharmaceuticals have been central to this investment program. Mr. Burrill called the Russian government's "significant commitment to invest capital to build an innovation-driven life sciences industry and modernize its healthcare system" a major factor for his decision to expand there. Regulations have been pared down to make it easier for foreign companies with advanced technology to establish laboratories and manufacturing centers in Russia. The government has extended its full support, often in the form of co-investment, to foreign high-tech companies seeking entry to the rapidly growing Russian market.

The Russian capital Moscow is the educational, economic and political hub of the region. It has a huge academic and scientific establishment and a highly educated workforce: over 241,200 people are employed in research and development. While private medicine is growing in Moscow, the government remains the largest consumer of healthcare products and all major decisions concerning government policy on healthcare are made in the capital. The Moscow City Government has undertaken major projects to transform abandoned and underutilized industrial space in the city into world-class laboratories and manufacturing centers for nanotechnology, biopharmaceuticals and other advanced applications. The City of Moscow is offering foreign companies special customs and tax regimes as well as full connections to infrastructure and fully equipped spaces in an effort to combat the outdated perceptions and stereotypes.

Skolkovo emerges as thriving high-tech community

One of the most prominent government effort in the high-tech arena is the creation of a Russian Silicon Valley in the form of the Skolkovo Innovation Centre, a complex of high-tech clusters where project participants are provided with the assistance necessary for development. More generally, Skolkovo seeks to concentrate international intellectual capital in Russia to create the conditions conducive to technological breakthroughs. Open Innovations, which was organized by Skolkovo along with other state agencies, can be seen as an effort to collect some intellectual capital by bringing some of the top figures in the biotechnology field together to share their expectations on future global trends.

Skolkovo resident companies include OncoMax, a developer of new diagnostic and therapeutic anti-cancer agents; TheraMAB, which is researching an innovative immunotherapeutic antibody for personalized medicine; and Innovative Technologies, a maker of neural prosthetic devices. These are just a few examples of the many Russian innovative ventures that have already taken root at Skolkovo. Another major investment in intellectual capital was Skolkovo's partnership with the Massachusetts Institute of Technology (MIT) to found a university and life sciences incubator. The MIT Skoltech Initiative aims to integrate education and research and establish a culture of innovation and entrepreneurship within Skolkovo. Biotechnology will be a central research area of the institute, which will help attract and retain world-class talent in Moscow.

Selecta sets up shop in Russia

Skolkovo is not the only Russian government-backed vehicle taking the lead in the future of the life sciences industry. In November 2012, Selecta Russia, which is wholly owned by Selecta Biosciences, opened a research center in Khimki, just outside of Moscow, at the ChemRar High Tech Center. The center will develop immunology related therapies consisting of Selecta's proprietary Synthetic Vaccine Particles (SVP™) nanotechnology platform and clinical stage compounds in-licensed from biotech and pharmaceutical companies.

Selecta clearly has seen Russia's promise for the biopharmaceutical industry. Its President and CEO, Dr. Werner Cautreels, has left Massachusetts to live in Moscow and run the Russian subsidiary. Dr. Cautreels said Selecta Russia will "incorporate the needs of patients in emerging markets into our product profiles." Russia is clearly not ancillary to Selecta's plans, but rather a major trajectory for the future growth of the company. Selecta will create innovative drugs based on nanomedicine platforms from MIT and Harvard Medical School and has established a subsidiary in Russia to access its scientific and clinical expertise and position themselves in the domestic market.

Russia has seen the future, and it's high-tech

With the weak global financial environment leading investors to seek havens from risk, younger companies in need of funding are beginning to look outside traditional sources. New players in emerging markets are filling the gap by supporting forward-looking enterprises. Unlike its emerging market peers, Russia has a long and distinguished tradition of advanced scientific research, especially in the theoretical sciences. Western observers are increasingly recognizing the Russian government's seriousness about developing its domestic high-technology and science-related industries.

A two-day Summit discussing key topics affecting today's delivery of health care and presenting promising Israeli life sciences companies addressing tomorrow's challenges. Keynote dinner address on November 5 by Dr. Gary Gottlieb, President and CEO of Partners HealthCare. Summit includes over 50 distinguished speakers, corporate presentations, networking, reception and gala dinner, and workshops with industry leaders on matters critical to adoption of new technologies by health care providers, the effect of health care reforms on new medical technologies, financing of advanced-stage life science companies and more.

The 18th annual BIO-Europe^® event will be the largest biotechnology partnering conference held in Europe. Over 3,000 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. BIO-Europe^® features the industry's most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward.

The 6th Annual OneMedForum is a gathering of leading investors and management of some of the most promising emerging life science companies in Asia and North America. Through panels, workshops, and up-close programming with top industry leaders, attendees explore strategies for company growth finance with healthcare investors looking for outsized returns.

We have a dedicated track for small, early stage companies seeking seed money to enter the private sector. This year, we pay special attention to non- traditional financing strategies. You will meet companies across the spectrum — the hottest companies with precedent-setting financing success, companies with industry-altering products just one step away, and the newest technologies spun out into the private sector.

The 10th Annual BIO Asia International Conference will bring together U.S. and European drug development companies with Asian biotech and pharmaceutical companies interested in research collaborations and licensing agreements. Connect via BIO One-on-One Partnering and showcase your company's accomplishments through company presentations in front of a global audience. A world-class program will highlight industry-related topics vital to your company.

Plan to attend MDMA's 2013 Annual Meeting in our Nation's Capital, April 15-17, 2013. MDMA's Annual Meeting will cover key issues impacting the United States' leadership position in med tech innovation, and how we can all help shape the regulatory and legislative agendas. This year's focus will address the critical role that medical technology plays in improving the quality of life and reducing the costs of care.

Now in its 13th year, the World Vaccine Congress & Expo is the world's biggest and most comprehensive event for the vaccine industry. Our expo market place is the only one of its kind for the vaccine industry.

Combining a high level conference with a focused exhibition and adding in guaranteed meetings with targeted buyers in a 1-2-1 Partnering format makes this event the one must-attend event for the whole vaccine market. Join the science and partnering streams for unseen and unheard case studies from the real pioneers, and corporate thought leaders.

The largest gathering of biotech professionals is coming to Chicago's McCormick Place, April 22 – 25, 2013, and it's an event you won't want to miss. Join 16,500 leaders from 65 countries at the 2013 BIO International Convention for four days of partnering opportunities, expert insights and the latest technology discoveries. Choose from 125 targeted and timely education sessions led by world-renowned experts. See the latest technology trends from 2,000+ leading suppliers and get a snapshot of industry progress around the world in 60+ state and country pavilions. All to help you grow your business, advance your research or boost your career. Register now at http://convention.bio.org.

FDLI's Annual Conference is the largest and longest-running legal conference for FDA-regulated industry and the entire food and drug law community. This advanced two-day program will cover legal, regulatory, policy and economic issues spanning the gamut of FDA's authority by bringing together experts from the Federal Government, industry, private-sector bar, consulting organizations and academia.

Now in its 16th edition, The MedTech Investing Europe Conference offers a perfect combination of the latest investment opportunities in game-changing technologies and unrivalled programme content giving first-hand insight and opinion from senior-level MedTech experts.

Pre-arranged one-to-one meetings and extensive networking opportunities will give investors and entrepreneurs ample opportunity to identify and meet with the companies and individuals that are right for you. This year's agenda has been comprehensively researched and designed to cover the most up to date issues within this ever-developing sector and will provide delegates with the vital intelligence and advice needed to succeed in 2013 and beyond.